Early procalcitonin assays may reduce antibiotic exposure in premature newborn infants

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: The diagnosis of early-onset neonatal sepsis (EOS) remains difficult. The main aim was to study the effect of a new algorithm for EOS, which includes the level of procalcitonin in umbilical cord blood, on the exposure to antibiotic therapy of premature newborn infants. Methods: This was a monocentric, observational and retrospective study with before-and-after design. The duration and dose of antibiotic therapy provided as well as the morbidity and mortality were compared in two groups, one included 01 May 2015–30 November 2015 when procalcitonin was not used, and one after the change 01 November 2016–30 May 2017 when procalcitonin was used in a hospital setting in Nice, France. Results: Sixty newborn infants were included in the before group and 54 in the after group. Antibiotic therapy was stopped after 24 h for 18 newborn infants in the after group and four in the before group, and after 48 h for 26 newborn infants in the after group and 10 in the before group. Conclusion: The implementation of a new decision-making algorithm including early procalcitonin assay of premature newborn infants significantly reduced exposure to antibiotics without modifying mortality or morbidity.

Cite

CITATION STYLE

APA

Hue-Bigé, A., François-Garret, B., Casagrande, F., Oertel, J., Mayerus, M., & Eleni Dit Trolli, S. (2024). Early procalcitonin assays may reduce antibiotic exposure in premature newborn infants. Acta Paediatrica, International Journal of Paediatrics, 113(5), 939–946. https://doi.org/10.1111/apa.17137

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free